ArticleBreast cancer (Tokyo, Japan)2026
Cost-effectiveness of mammography-based breast cancer screening in Jordan: a healthcare system perspective.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBreast cancer is the most common cancer among women in Jordan, with many cases detected at advanced stages, leading to higher costs and poorer outcomes. Despite mammography's proven benefits for early detection, its use remains low. This study evaluates the cost-effectiveness and budget impact of implementing mammography screening in Jordan's healthcare system.
methodsA cost-effectiveness analysis was conducted from the perspective of the Jordanian healthcare system, comparing mammography-based screening with no screening (opportunistic detection) among women ≥ 40 years. A Markov model estimated disease progression, costs, and quality-adjusted life years (QALYs), using primarily local/regional data, supplemented by international sources when necessary. Results were expressed as incremental cost-effectiveness ratios (ICERs), i.e., cost per QALY gained. Sensitivity analyses tested model robustness. A budget impact analysis (BIA) assessed the financial implications of implementing nationwide screening.
resultsComparing mammography-based screening with no screening among women ≥ 40 years, ICER was estimated at $5341 per QALY gained, which is well below Jordan's willingness-to-pay threshold. Over a lifetime horizon, mammography screening among eligible women aged 40-50 years was projected to prevent 779 breast cancer deaths. Both one-way and probabilistic sensitivity analyses confirmed the robustness of the base-case results under uncertainty. Over five years, nationwide screening yielded net savings of $17.6 million compared to current screening estimates.
conclusionMammography-based breast cancer screening appears to be a cost-effective strategy in Jordan, with potential to reduce breast cancer mortality. These findings suggest possible improvements in population health outcomes and more efficient use of healthcare resources.
Indexed as
Identifiers
42565975What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.